Glypican-3 (GPC3) has emerged as one of the most promising therapeutic targets in oncology, particularly in hepatocellular carcinoma and select solid tumors. As a cell surface heparan sulfate proteoglycan that is overexpressed in approximately 75% of hepatocellular carcinoma cases while remaining virtually absent in normal adult tissues, GPC3 represents an ideal target for precision medicine approaches. The evolution of anti-GPC3-targeted therapies, from early monoclonal antibodies to sophisticated next-generation formats, marks a transformative shift in cancer treatment strategy.
Understanding Glypican-3: The Target Molecule
Glypican-3 is a cell surface h...
